Sten Verland PhD is one of the four co-founders of Sunstone Life Science Ventures. After 17 years as General Partner, Sten has stepped down to a part-time role as Venture Partner. In this new role Sten is supporting the Sunstone team on sourcing and evaluating new investment opportunities with a particular focus on opportunities related to immuno-oncology, autoimmune diseases, and orphan diseases.

During his career, Sten has held several executive roles in the CRO industry, and he has been active as a serial entrepreneur and business angel co-founding 10 life science start-ups. While at Sunstone, Sten has played a key role in executing three M&A’s (Rigontec, Action Pharma and Zymenex) and two IPO’s (Orphazyme; NASDAQ Nordic & NASDAQ NY).

Sten holds a master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen.

Contact:

   